The Firm will showcase its investigational pipeline belongings and invite conversations with potential companions on the Congress, September 23-24, in Boston.
STAMFORD, Conn., Sept. 22, 2026 /PRNewswire/ — Knoa Pharma LLC (“Knoa Pharma”), a public health-focused pharmaceutical firm devoted to supporting sufferers and enhancing public well being, will current its investigational pipeline belongings on the 2026 LSX Congress USA in Boston, Massachusetts on September 23, at 1:45 p.m. ET, on the Biotech Development stage. Knoa Pharma is actively in search of partnerships to advance the event of investigational therapeutics for a number of belongings throughout a number of illness areas together with genitourinary problems, substance use problems, and oncology. The firm is discussing two belongings, sunobinop and tinostamustine, each of which might current substantial income alternatives.*
Tinostamustine is a novel, first-in-class investigational drug combining DNA alkylating exercise and HDAC inhibition in a single molecule. It has the potential to be a first-line agent to deal with sufferers with glioblastoma (GBM), a extremely aggressive type of mind most cancers. In Part 1 research as an adjuvant to straightforward chemoradiation, tinostamustine confirmed promising exercise in difficult-to-treat newly recognized sufferers. The drug has obtained orphan drug designation from FDA and has the potential to be the primary new pharmacologic therapy possibility for GBM in additional than 20 years. In Part 1/2 scientific trials, tinostamustine has additionally proven promise in a number of different stable and hematological tumors.
At the moment, tinostamustine can also be part of GBM AGILE (Glioblastoma Adaptive World Revolutionary Studying Surroundings – NCT03970447), sponsored by the World Coalition for Adaptive Analysis. It is a seamless section 2/3 research carried out underneath a grasp protocol enabling a number of therapies or combos of therapies to be evaluated concurrently in opposition to a shared management arm. With its modern design and environment friendly operational infrastructure, knowledge from GBM AGILE can doubtlessly be used as the muse for brand spanking new drug purposes and registrations to the U.S. FDA and different well being authorities.
Sunobinop is a novel, first-in-class nociceptin receptor agonist. The orally energetic investigational drug is in Part 1/2 scientific improvement for a number of indications, together with alcohol use dysfunction (AUD), interstitial cystitis/bladder ache syndrome (IC/BPS), and overactive bladder (OAB). Associated to AUD, sunobinop is meant to handle alcohol craving, consumption, and sleep points; it has the potential to be the primary new modality in AUD in virtually 20 years. Associated to OAB and IC/BPS, sunobinop is a novel, first-in-class agent that targets the sensory nerves within the bladder to have an effect on urination and ache, and doubtlessly decreasing nocturia.
“Our R&D is grounded in rigorous science. Sunobinop and tinostamustine are differentiated, clinical-stage belongings with encouraging indicators throughout a number of illness areas,” stated David Saussy, Head of Licensing and Enterprise Improvement at Knoa Pharma. “We sit up for sharing Knoa Pharma’s pipeline and connecting with potential companions at LSX USA who share our dedication to advancing scientific innovation.”
Firms fascinated about studying extra about Knoa Pharma’s pipeline and partnership alternatives are inspired to attach with the staff throughout LSX Congress USA 2026. For extra data on pipeline merchandise, e-mail partnering@pharma.com.
*This launch discusses investigational makes use of of brokers in improvement and isn’t meant to convey conclusions about efficacy or security. There isn’t any assure that sunobinop or tinostamustine will efficiently full improvement or acquire FDA approval.
About Knoa Pharma LLC
Knoa Pharma was based with a public well being objective to assist abate the opioid disaster. That mission drives all the things we do. We increase entry to lifesaving overdose reversal medicines and ship reasonably priced therapies for opioid use dysfunction, whereas guaranteeing the secure and accountable distribution of medicines which might be important to affected person care, together with opioid analgesics. We additionally innovate to handle unmet affected person wants and improve our strong generics portfolio. Owned by a not-for-profit basis, each side of the enterprise is centered on enhancing public well being, saving lives, supporting restoration, and bringing ahead medicines that make a significant distinction. Study extra at www.knoapharma.com.
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/knoa-pharma-to-present-pipeline-assets-at-lsx-congress-usa-2026-302886063.html
SOURCE Knoa Pharma
